Rheumatologists' Benefit-Risk Preferences for Biologic Treatments for Rheumatoid Arthritis

被引：0
|
作者：
Hauber, A. Brett [1 ]
Cross, James T. [2 ]
Yocum, David E. [2 ]
Johnson, F. Reed [1 ]
Yang, Jui-Chen [1 ]
Villaneuva, Isidro [2 ]
Katz, Patricia P. [3 ]
机构：
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
[2] Genentech Inc, San Francisco, CA 94080 USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
ARTHRITIS AND RHEUMATISM | 2011年 / 63卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1247
引用
收藏
页码：S487 / S488
页数：2
相关论文
共 50 条
  • [31] Benefit-Risk Assessment of Treatments for Heparin-Induced Thrombocytopenia
    Harry L. Messmore
    Walter P. Jeske
    William H. Wehrmacher
    Jeanine M. Walenga
    [J]. Drug Safety, 2003, 26 : 625 - 641
  • [32] Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy
    Barton, Jennifer L.
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2009, 3 : 335 - 344
  • [33] Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
    Conaghan, Philip
    Cohen, Stanley
    Burmester, Gerd
    Mysler, Eduardo
    Nash, Peter
    Tanaka, Yoshiya
    Rigby, William
    Patel, Jayeshkumar
    Shaw, Tim
    Betts, Keith A.
    Patel, Pankaj
    Liu, Jianzhong
    Sun, Rochelle
    Fleischmann, Roy
    [J]. RHEUMATOLOGY AND THERAPY, 2022, 9 (01) : 191 - 206
  • [34] Benefit/risk of cyclosporine in rheumatoid arthritis
    Gremese, E
    Ferraccioli, GF
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2004, 22 (05) : S101 - S107
  • [35] Benefit/risk of leflunomide in rheumatoid arthritis
    Kremer, JM
    Cannon, GW
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2004, 22 (05) : S95 - S100
  • [36] Cancer risk with biologic DMARDs in rheumatoid arthritis
    [J]. Reactions Weekly, 2017, 1672 (1) : 11 - 11
  • [37] The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis
    Furst, Daniel E.
    [J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2010, 39 (05) : 327 - 346
  • [38] Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments
    Bieber, J
    Kavanaugh, A
    [J]. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2004, 30 (02) : 257 - +
  • [39] Ethnographic Observational Study of the Biologic Initiation Conversation Between Rheumatologists and Biologic-Naive Rheumatoid Arthritis Patients
    Kottak, Nicholas
    Tesser, John
    Leibowitz, Evan
    Rosenberg, Melissa
    Parenti, Dennis
    DeHoratius, Raphael
    [J]. ARTHRITIS CARE & RESEARCH, 2018, 70 (07) : 997 - 1004
  • [40] Patient benefit-risk in arthritis-a rheumatologist's perspective
    Bijlsma, Johannes W. J.
    [J]. RHEUMATOLOGY, 2010, 49 : ii11 - ii17
12345